argenx reports first quarter 2020 financial results and provides business update
- Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year - - Enrollment paused in ongoing trials under Janssen …